Given there are no treatment options that reverse pathophysiology in ALS and FTD, the distinct link between TDP-43 pathology and stress granules in the progression of ALS and FTD suggest both TDP-43 mistranslocation and stress granules could be suitable targets for developing disease-modifying treatments [14]. This evidence concerns the gene TARDBP and frontotemporal dementia.